However, current findings suggest reduced CYP11B1 functioning in MS patients compared to controls, as four 11β-hydroxy-androstanes exhibited significantly lower levels in MS patients, one showed no change between the groups, and none had higher levels. Here, CYP11B1 is linked to myeloid sarcoma.